Archive | Indalo Therapeutics

Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO

Robert-Jacks_4268Cc-Web_for wire distro

Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced that Robert Jacks has been appointed President & CEO. Mr. Jacks brings to Indalo 18 years of experience in biopharmaceutical product development, corporate strategy, business development, […]

Comments Off on Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO Continue Reading →